Categories LATEST

Shopify (SHOP) swings to loss on higher Q3 costs

Multi-channel ecommerce platform Shopify (NYSE: SHOP) misses third quarter 2019 earnings estimates and reported a loss for the quarter sending the stock towards the negative territory. However, revenue topped the targets. For the recently ended quarter, Shopify posted a loss of $0.29 per share compared to a profit of $0.05 per share in the third quarter of 2018.

Analysts had estimated the company to post earnings of 11 cents per share. Revenue jumped 45% to $390.6 million versus the consensus view of $383.76 million. On a GAAP basis, loss per share expanded to $0.64 from a loss of $0.22 per share in the prior-year quarter. Shopify shares were down about 5% in the pre-market trading session.

Shopify (SHOP) swings to loss in Q3 2019 on higher costs

GAAP operating expenses for the three months ended September 30, 2019, increased to $252 million from $181 million in the prior year period, while non-GAAP operating expenses increased to $209 million from $154 million.

For fiscal 2019, Shopify expects revenue to be between $1.545 billion and $1.555 billion. GAAP operating loss is expected to be in the range of $158 million to $168 million.

For the fourth quarter of 2019, revenue is touted be in the range of $472 million to $482 million and GAAP operating loss is estimated to be in the range of $47 million to $57 million.

Shopify, which surpassed one million merchants in its platform during the third quarter, reported a 48% year-over-year increase in gross merchandise volume (GMV) to $14.8 billion. Gross payments volume (GPV) grew to $6.2 billion from $4.1 billion in the year-ago quarter.

As part of its expansion initiatives, Shopify completed the acquisition of warehouse fulfillment solutions provider 6 River Systems two weeks back.

SHOP stock had surged 135% so far this year and 144% from this time last year.

We’re on Apple News! Follow us to receive the latest stock market, earnings and financial news at your fingertips

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top